People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Civitas Therapeutics, Inc. | — | Biotechnology | Series C | $117.8M | $2.3B | 2013 |
Robert P. Hopfner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert P. Hopfner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Hirsch | 1 | 16 |
| Timothy Shannon | 1 | 9 |
| Rob Hopfner | 1 | 6 |
| Glenn Batchelder | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| Aidan King | 1 | 3 |
| MARTIN FREED | 1 | 3 |
| Mary Taylor | 1 | 2 |
| Bryan Stuart | 1 | 2 |
| RICHARD BATYCKY | 1 | 2 |
| TIMOTHY S. NELSON | 1 | 1 |
| RAJEEV S. SHAH | 1 | 1 |
| TIM S. SHANNON | 1 | 1 |
| Blair Jackson | 1 | 1 |
| Robert P. Roche, Jr. | 1 | 1 |
| Rajeev P. Shah | 1 | 1 |
| ROBERT S. ROCHE | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.